Lucid Diagnostics, Inc.

As of November 13, 2023, Lucid Diagnostics, Inc. is considered a risky investment due to its negative valuation ratios and underperformance compared to peers, despite a year-to-date return of 30.7%, which is overshadowed by a three-year decline of -42.16%.

As of November 13, 2023, Lucid Diagnostics, Inc. is rated as risky and overvalued due to negative financial ratios, including a Price to Book Value of -25.96 and a P/E ratio of -2.8046, despite a year-to-date return of 45.35%.

As of May 16, 2025, Lucid Diagnostics, Inc. shows a mildly bullish trend overall, supported by daily moving averages and monthly MACD, despite mixed signals from weekly indicators.

Lucid Diagnostics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $27 million as of March 2025. The company has a market cap of $133.08 million and does not pay dividends.

As of Jun 18, Lucid Diagnostics, Inc. has a market capitalization of 133.08 million, with net sales of 4.18 million and a net profit of -61.83 million over the last four quarters. The company reported shareholder's funds of 5.39 million and total assets of 30.71 million as of Dec 24.